Streetbeat News

Regulatory

FRSX

Foresight Autonomous Holdings Ltd. has received a notice of U.S. patent allowance for its 3D image analysis system and calibration technology. The patent pertains to calibrating imaging devices, matching elements in stereo imaging systems, and creating 3D reconstructions.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 12:30 pm

OPTT

Ocean Power Technologies, Inc. (OPTT) has entered a contract with WildAid and Caribbean Law Enforcement to combat illegal fishing using uncrewed technologies. OPTT will provide an Uncrewed Surface Vessel equipped with an integrated quadcopter aerial drone. The technology will help law enforcement agencies and conservation organizations protect marine life from illegal harvesting and ensure the sustainability of critical ecosystems.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 12:23 pm

IMMP

Immutep Limited has received a AUD$1.13M cash rebate from the Australian Federal Government's R&D tax incentive program. The rebate is for expenditure incurred on eligible R&D activities conducted in the 2022 fiscal year, mainly related to the Company's TACTI-002 and TACTI-003 clinical study using its lead compound eftilagimod alpha. The funds will be used to further its current active clinical trial programs for its lead product candidate, efti.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 12:19 pm

SHOT

Safety Shot has been issued a second U.S. patent for its product JW-700, which enhances the effectiveness of Minoxidil in the hair growth market. The product, which has exceeded sales expectations in India, is set to be introduced in 30 other countries through a partnership with Cosmofix & San Pellegrino. The company has also added Dr. Ready's, a company with annual revenues of $2.99B, to its licensee list. Clinical trial results demonstrating the product's efficacy in hair growth are expected in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 12:19 pm

FDMT

4D Molecular Therapeutics (NASDAQ:FDMT) announced that interim data from the Phase 1/2 AEROW clinical trial of aerosolized 4D-710 for treatment of cystic fibrosis lung disease will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC). The company will also host a live webcast to discuss the data in detail and provide a program update. The interim data will include additional safety and clinical activity follow-up on Cohort 1 and initial safety and biomarker data from Cohort 2.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 12:18 pm

CNTA

Centessa Pharmaceuticals has announced preclinical data from in vivo and in vitro studies of ORX750. The data showed significant activity at low doses of ORX750 in highly predictive translational models of Narcolepsy Type 1 (NT1). ORX750 is advancing in IND-enabling studies, with clinical proof of concept data planned for 2024.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 12:12 pm

TU

TELUS' Data for Good program has become the first in the world to achieve ISO 31700-1 Privacy by Design certification. The certification, developed by the International Standards Organization in partnership with former Information and Privacy Commissioner of Ontario, Dr. Ann Cavoukian, recognizes best practices around data de-identification.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 12:07 pm

AVXL

Anavex Life Sciences Corp. (NASDAQ: AVXL) has reported a new publication in the Neurobiology of Aging journal, demonstrating the potential of ANAVEX 3-71 to prevent cognitive decline in Alzheimer's disease. The study shows that ANAVEX 3-71 treatment prevents cognitive impairment, reduces amyloid, and neuroinflammation even after a long drug washout. The drug has already successfully completed a Phase 1 human clinical trial demonstrating good safety and tolerability signals at all doses studied. The company is also on track to release top-line data of ANAVEX 2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the current quarter of 2023.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 12:07 pm

BABA

NVDA

Alibaba Group Holding Limited's stock is trading lower as it gave up gains associated with reports over Beijing's stimulus plan. The Chinese government plans to issue an additional 1 trillion yuan in sovereign debt during Q4. The US Government informed Nvidia Corp that the fresh restrictions applied to products having a 'total processing performance' of 4800 or more and designed or marketed for data centers are effective immediately, impacting shipments of Nvidia's A100, A800, H100, H800, and L40S products. This will be a big blow to the semiconductor aspirations of Alibaba.

Portfolio Pulse from Anusuya Lahiri

October 25, 2023 | 11:51 am

IINN

Inspira Technologies Oxy B.H.N. Ltd. (IINN) has been granted a U.S. patent for its INSPIRA ART500 medical device, a respiratory support system for patients suffering from respiratory failure.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 11:50 am